A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients

Trial Profile

A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs SM 88 (Primary)
  • Indications Advanced breast cancer; Cancer; Pancreatic cancer
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 20 Jan 2018 Results of a retrospective analysis of 12 patients with advanced or metastatic pancreatic cancer from this and compassionate use study, presented at the 2018 Gastrointestinal Cancers Symposium
    • 19 Jan 2018 According to a Tyme Technologies media release, results from patients (n=10) with pancreatic cancer from this or compassionate use program were presented in a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
    • 19 Jan 2018 Results from patients (n=10) with pancreatic cancer from this or compassionate use program presented in a Tyme Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top